On November 11—13, 2023, experts from the Brigham’s Heart and Vascular Center will join thousands of colleagues in raising awareness and improving cardiovascular health at this year’s American Heart Association (AHA) Scientific Sessions.

Cardiovascular experts from Brigham and Women’s Hospital will present at this year’s Transcatheter Cardiovascular Therapeutics (TCT) Conference on interventional cardiology, held October 23–26 in San Francisco, CA.

Using a novel method, Brigham and Women’s Hospital researchers completed the first comparative proteomics study of pathogenesis in calcified carotid arteries and aortic valves (AVs), identifying unique drivers of atherosclerosis versus AV stenosis and implicating extracellular vesicles in both diseases.

In 1923, Dr. Elliot C. Cutler conducted the world’s first successful mitral valvuloplasty at the Brigham (then Peter Bent Brigham Hospital). On October 20, 2023, the Brigham will mark this important milestone with an all-day CME event looking at past, present, and future approaches to managing mitral valve disease.

Brigham and Women’s Hospital researchers found moderate eGFR decline when transitioning from a renin–angiotensin system inhibitor (RASi) to SV was not consistently associated with adverse outcomes. In addition, long-term benefits of SV were retained in patients with HF across a broad range of initial eGFR declines.

A recent study co-led by Guo-Ping Shi, ScD, and Zhaojie Meng, PhD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, is the first to identify a receptor for eosinophil cationic protein and define its pathogenic role in atherosclerosis.

Researchers used an approach to generate oxidative stress in the vascular endothelium, planning to explore diseases such as hypertension and aortic aneurysms. Surprisingly, the transgenic mice developed neurodegeneration, mitochondrial dysfunction, and cardiac hypertrophy caused by neurovascular oxidative stress.